Table 1.
Correlations between baseline characteristics and BCVA changes of the injected eye at 1 and 3 months after gene therapy
| Variable | Changes in BCVA at 1 month | P | Changes in BCVA at 3 months | P | ||
|---|---|---|---|---|---|---|
| Improvement | Non‐improvement | Improvement | Non‐improvement | |||
| Sex (M/F) | 22/2 | 26/3 | 1.000 | 27/1 | 21/4 | 0.283 |
| Age at onset (years) | 16.04 ± 4.31 | 16.28 ± 5.48 | 0.795 | 16.36 ± 4.62 | 15.96 ± 5.36 | 0.648 |
| Duration of disease (months) | 29.33 ± 26.86 | 43.79 ± 60.09 | 0.271 | 33.54 ± 29.15 | 41.40 ± 63.47 | 0.993 |
| VFI (%) | 29.21 ± 27.63 | 13.79 ± 15.79 | 0.053 | 27.68 ± 26.02 | 13.04 ± 16.51 | 0.028 |
| MD (dB) | −23.81 ± 9.21 | −28.05 ± 5.59 | 0.136 | −23.85 ± 8.53 | −28.68 ± 5.73 | 0.026 |
| Baseline BCVA (logMAR) | 1.94 ± 0.31 | 1.76 ± 0.42 | 0.164 | 1.94 ± 0.27 | 1.73 ± 0.46 | 0.099 |
Abbreviations: BCVA, best‐corrected visual acuity; MD, mean deviation; VFI, visual field index.